Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

H-922

Supelco

α-Hydroxymidazolam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H13ClFN3O
CAS Number:
59468-90-5
Molecular Weight:
341.77
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

2-8°C

SMILES string

OCc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4-n12

InChI

1S/C18H13ClFN3O/c19-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)20)22-9-12-8-21-17(10-24)23(12)16/h1-8,24H,9-10H2

InChI key

QHSMEGADRFZVNE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

α-Hydroxymidazolam is an active, major metabolite in urine and blood of the benzodiazepine midazolam. Midazolam is sold as Dormicum, Hypnovel®, and Versed as a sedative and treatment for insomnia and seizures. This Certified Spiking Solution® is suitable as starting material for use in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Hypnovel is a registered trademark of Hoffman-LaRoche & Co. AG
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

H-902

α-Hydroxymidazolam solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-921

α-Hydroxymidazolam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-908

Midazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-918

Midazolam-d4 maleate, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

H-156

4-Hydroxymidazolam-D4 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

H-172

4-Hydroxymidazolam solution, 1 mg/mL (90:10 Acetonitrile:DMSO), certified reference material, ampule of 1 mL, Cerilliant®

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David Hostler et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(5), 781-788 (2010-02-19)
The clinical use of therapeutic hypothermia has been rapidly expanding due to evidence of neuroprotection. However, the effect of hypothermia on specific pathways of drug elimination in humans is relatively unknown. To gain insight into the potential effects of hypothermia
Kristin Samuelsson et al.
Xenobiotica; the fate of foreign compounds in biological systems, 42(11), 1128-1137 (2012-05-31)
The pharmacokinetics and biotransformation of midazolam were investigated following single oral doses of 0.1, 1 and 10 mg/kg to chimeric mice with humanised livers (PXB mice) and to severe combined immunodeficient (SCID) mice used as controls. Pharmacokinetic analysis, on whole
Varun Garg et al.
Journal of clinical pharmacology, 52(10), 1566-1573 (2011-12-14)
In this open-label study, 24 healthy volunteers received a single intravenous (IV) dose of 0.5 mg of midazolam on day 1 and a single oral dose each of 2 mg of midazolam and 0.5 mg of digoxin on day 3.
Theo de Boer et al.
Biomedical chromatography : BMC, 25(10), 1112-1123 (2011-02-03)
An early clinical development study (phase I) was conducted to determine the usefulness of dried blood spot (DBS) sampling as an alternative to venous sampling for phenotyping and genotyping of CYP450 enzymes in healthy volunteers. Midazolam (MDZ) was used as
Stephanie Katzenmaier et al.
European journal of clinical pharmacology, 66(11), 1137-1141 (2010-08-04)
Midazolam metabolic clearance to 1'-hydroxymidazolam is an accurate measure of CYP3A activity which requires extensive plasma and urine sampling. The objective of this study was to find a new limited sampling strategy (LSS) to predict midazolam metabolic clearance to 1'-hydroxymidazolam
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service